People · Operator
Named in public records as an officer, director or promoter · active 2009–2019 · Biotechnology, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Ajax Therapeutics, Inc. | — | Biotechnology | Series C | $140.4M | $907.0M | 2019 |
| Lux Biosciences Inc | — | Biotechnology | Series B | $81.1M | $635.0M | 2009 |
| Nora Therapeutics, Inc. | — | Biotechnology | Series B | $38.3M | $39.7M | 2009 |
| Kythera Biopharmaceuticals Inc | — | Pharmaceuticals | Series B | $37.4M | $1.3B | 2011 |
| Gloucester Pharmaceuticals Inc | — | Biotechnology | Series B | $26.0M | $806.7M | 2009 |
| Satori Pharmaceuticals Inc | — | Pharmaceuticals | Series A | $22.3M | $464.6M | 2012 |
| Trubion Pharmaceuticals, Inc | — | Biotechnology | Series A | $10.0M | $361.5M | 2009 |
David Schnell at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside David Schnell on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Thomas Dyrberg | 2 | 5 |
| Martin Vogelbaum | 2 | 3 |
| Steven Gillis | 1 | 23 |
| Robert Nelsen | 1 | 22 |
| Seth Harrison | 1 | 19 |
| Peter Thompson | 1 | 16 |
| Edward Mathers | 1 | 12 |
| Patrick Heron | 1 | 11 |
| David Guyer | 1 | 8 |
| Chen Yu | 1 | 7 |
| Chris Ehrlich | 1 | 6 |
| Axel Bolte | 1 | 6 |
| Lutz Giebel | 1 | 6 |
| Ilan Zipkin | 1 | 6 |
| Camille Samuels | 1 | 6 |
| Donald J. Hayden, Jr. | 1 | 5 |
| Ramy Farid | 1 | 5 |
| Kendall Mohler | 1 | 5 |
| Daphne Zohar | 1 | 4 |
| Dennis Fenton | 1 | 4 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.